Table 4.

Clinical relevance of four variants among trauma patients

	Polymorphic sites	Genotypes	N	Age (yr)	Sex (M/F)	ISS	Sepsis, n/%	MOD score
Chongqing		ins/ins	423	40.2 ± 14.6	334/89	22.3 ± 10.5	178 (42.1)	6.4 ± 2.4
	63 bp ins/del	ins/del	70	40.9 ± 11.1	59/11	20.5 ± 10.5	23 (32.9)	6.1 ± 2.8
		del/del	3	47.3 ± 18.8	2/1	24.3 ± 8.5	1 (33.3)	6.0 ± 1.7
		GG	247	39.5 ± 14.4	198/49	22.2 ± 11.4	100 (40.5)	6.7 ± 2.6
	rs2070600	GA	206	41.0 ± 14.4	161/45	21.9 ± 9.4	84 (40.8)	6.1 ± 2.3
		AA	43	42.5 ± 11.5	36/7	22.0 ± 10.4	18 (41.9)	5.7 ± 1.6
		TT	364	40.4 ± 14.3	291/73	22.2 ± 10.4	148 (40.7)	6.3 ± 2.4
	rs1800624	TA	117	40.5 ± 14.3	91/26	21.7 ± 11.0	51 (43.6)	6.5 ± 2.5
		AA	15	39.7 ± 12.0	13/2	20.2 ± 8.8	3 (20.0)	7.0 ± 2.6
		TT	365	40.0 ± 14.1	291/74	22.4 ± 10.5	163 (44.7)	6.9 ± 2.4
	rs1800625	TC	116	42.4 ± 14.4	89/27	21.3 ± 10.7	35 (30.2)	6.0 ± 2.2
		CC	15	37.3 ± 9.9	15/0	17.2 ± 9.8	4 (26.7)	5.3 ± 1.5
							a1	a2, b1, c1
Zhejiang		ins/ins	203	41.0 ± 12.9	165/38	23.3 ± 8.6	74 (36.4)	6.9 ± 3.4
	63bp ins/del	ins/del	29	41.1 ± 14.9	25/4	22.7 ± 9.3	14 (48.3)	8.4 ± 3.0
		del/del	0	-	-	-	0 (0)	-
		GG	126	41.3 ± 13.4	102/24	22.7 ± 8.6	48 (38.1)	7.1 ± 3.1
	rs2070600	GA	85	40.7 ± 12.4	70/15	23.0 ± 8.5	35 (41.2)	6.9 ± 3.6
		AA	21	40.6 ± 14.5	18/3	27.5 ± 8.6	5 (23.8)	6.9 ± 2.8
	rs1800624	TT	181	41.0 ± 13.3	150/31	23.4 ± 8.7	70 (38.7.)	7.0 ± 3.5
		TA	48	40.6 ± 13.0	38/10	22.4 ± 8.3	16 (33.3)	7.4 ± 3.2
		AA	3	44.7 ± 7.1	2/1	28.0 ± 14.1	2 (67.7)	6.7 ± 2.3
		TT	163	41.4 ± 13.2	138/25	23.7 ± 8.5	70 (42.9)	7.3 ± 3.3
	rs1800625	TC	64	40.9 ± 13.2	47/17	21.8 ± 8.6	16 (25.0)	6.9 ± 3.2
		CC	5	37.7 ± 15.7	4/1	24.3 ± 12.0	2 (40.0)	6.3 ± 2.5
							a3	a4, c2

A, dominant effect (variant homozygotes +heterozygotes vs. wild homozygotes) as analyzed by ANOVA, ^a1P = 0.003, ^a2P = 0.015, ^a3P = 0.016, ^a4P = 0.042; b, recessive effect (variant homozygotes vs. heterozygotes + wild homozygotes); as analyzed by ANOVA, ^b1P = 0.032; c, Allele Dose Effect as analyzed by linear regression, ^c1P = 0.045, ^c2P = 0.048.